Top

Published in:

26-02-2024 | Aplastic Anemia | Progress in Hematology

Progress in medical therapy in aplastic anemia: why it took so long?

Author: Phillip Scheinberg

Published in: International Journal of Hematology | Issue 3/2024

Abstract

The treatment of aplastic anemia (AA) has significantly advanced in the last 50 years, evolving from a fatal condition to one where survival rates now exceed 80–85%. Hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) have become the primary treatments, with the latter widely adopted due to factors like the scarcity of compatible donors, patient age, comorbidities, and limited HSCT access. A therapy breakthrough was the introduction of antithymocyte globulin (ATG), with its effectiveness further boosted by cyclosporine. However, it took years to achieve another major milestone in management. Initially, treatments aimed to intensify immunosuppression following the success of the ATG–cyclosporine combination, but these methods fell short of expectations. A major turning point was combining immunosuppression with stem cell stimulation, surpassing the efficacy of IST alone. Earlier, growth factors had shown limited success in AA treatment, but thrombopoietin receptor agonists represented a significant advancement. Initially applied alone as salvage, these were later combined with IST, forming the most effective current regimen for medically managing SAA. Horse ATG is the preferred formulation combined with cyclosporine and eltrombopag. This progress in AA treatment offers improved outcomes for patients afflicted with this once-lethal disease.

Young NS. Aplastic anaemia. Lancet. 1995;346(8969):228–32.CrossRefPubMed

Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, Young NS. The epidemiology of aplastic anemia in Thailand. Blood. 2006;107(4):1299–307. https://doi.org/10.1182/blood-2005-01-0161.CrossRefPubMedPubMedCentral

Barnes DW, Mole RH. Aplastic anaemia in sublethally irradiated mice given allogeneic lymph node cells. Br J Haematol. 1967;13(4):482–91.CrossRefPubMed

Mathe G, Amiel JL, Schwarzenberg L, Choay J, Trolard P, Schneider M, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J. 1970;2(5702):131–6.CrossRefPubMedPubMedCentral

Speck B, Gluckman E, Haak HL, van Rood JJ. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet. 1977;2(8049):1145–8.CrossRefPubMed

Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med. 1983;308(3):113–8.CrossRefPubMed

Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324(19):1297–304.CrossRefPubMed

Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. French Cooperative Group for the Study of Aplastic and Refractory Anemias. Scand J Haematol. 1986;36(4):346–52.

Bluteau O, Sebert M, Leblanc T, Peffault-de-Latour R, Quentin S, Lainey E, et al. A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. Blood. 2018;131(7):717–32. https://doi.org/10.1182/blood-2017-09-806489.CrossRefPubMed

10.

Gutierrez-Rodrigues F, Munger E, Ma X, Groarke EM, Tang Y, Patel BA, et al. Differential diagnosis of bone marrow failure syndromes guided by machine learning. Blood. 2023;141(17):2100–13. https://doi.org/10.1182/blood.2022017518.CrossRefPubMed

11.

Molteni E, Bono E, Galli A, Elena C, Ferrari J, Fiorelli N, et al. Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity. Blood. 2023;142(7):643–57. https://doi.org/10.1182/blood.2022019304.CrossRefPubMedPubMedCentral

12.

Hakkarainen M, Kaaja I, Douglas SPM, Vulliamy T, Dokal I, Soulier J, et al. The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia. Blood. 2023;141(23):2853–66. https://doi.org/10.1182/blood.2022019425.CrossRefPubMed

13.

Ronen D, Benvenisty N. Genomic stability in reprogramming. Curr Opin Genet Dev. 2012;22(5):444–9. https://doi.org/10.1016/j.gde.2012.09.003.CrossRefPubMed

14.

Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood. 1996;88(6):1983–91.CrossRefPubMed

15.

Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364(9431):355–64. https://doi.org/10.1016/S0140-6736(04)16724-X.CrossRefPubMed

16.

Shah YB, Priore SF, Li Y, Tang CN, Nicholas P, Kurre P, et al. The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis. Blood Adv. 2021;5(16):3216–26. https://doi.org/10.1182/bloodadvances.2021004201.CrossRefPubMedPubMedCentral

17.

Peffault-de-Latour R, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood. 2010. https://doi.org/10.1182/blood-2010-01-266098.CrossRefPubMed

18.

Scheinberg P, Chen J. Aplastic anemia: what have we learned from animal models and from the clinic. Semin Hematol. 2013;50(2):156–64. https://doi.org/10.1053/j.seminhematol.2013.03.028.CrossRefPubMed

19.

Scheinberg P. Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries. Br J Haematol. 2021;194(6):954–69. https://doi.org/10.1111/bjh.17403.CrossRefPubMed

20.

Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–8. https://doi.org/10.1056/NEJMoa1103975.CrossRefPubMedPubMedCentral

21.

Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012;119(23):5391–6. https://doi.org/10.1182/blood-2012-02-407684.CrossRefPubMed

22.

Hayakawa J, Kanda J, Akahoshi Y, Harada N, Kameda K, Ugai T, et al. Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. Int J Hematol. 2017;105(5):578–86. https://doi.org/10.1007/s12185-017-2179-3.CrossRefPubMed

23.

Yang N, Chen J, Zhang H, Dai Z, Yao H, Ma X, et al. Horse versus rabbit antithymocyte globulin in immunosuppressive therapy of treatment-naive aplastic anemia: a systematic review and meta-analysis. Ann Hematol. 2017;96(12):2031–43. https://doi.org/10.1007/s00277-017-3136-1.CrossRefPubMed

24.

Narita A, Zhu X, Muramatsu H, Chen X, Guo Y, Yang W, et al. Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia. Br J Haematol. 2019;187(2):227–37. https://doi.org/10.1111/bjh.16055.CrossRefPubMed

25.

Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–9. https://doi.org/10.1056/NEJMoa1200931.CrossRefPubMedPubMedCentral

26.

Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–25. https://doi.org/10.1182/blood-2013-10-534743.CrossRefPubMedPubMedCentral

27.

Winkler T, Fan X, Cooper J, Desmond R, Young DJ, Townsley DM, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019;133(24):2575–85. https://doi.org/10.1182/blood.2019000478.CrossRefPubMedPubMedCentral

28.

Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019;6(11):e562–72. https://doi.org/10.1016/S2352-3026(19)30153-X.CrossRefPubMed

29.

Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, et al. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. Br J Haematol. 2020. https://doi.org/10.1111/bjh.17190.CrossRefPubMedPubMedCentral

30.

Zhao LP, Sicre-De-Fontbrune F, Contejean A, Abraham J, Terriou L, Chabrot C, et al. Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Bone Marrow Transplant. 2019;54(7):1161–3. https://doi.org/10.1038/s41409-019-0452-1.CrossRefPubMed

31.

Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–50. https://doi.org/10.1056/NEJMoa1613878.CrossRefPubMedPubMedCentral

32.

Patel BA, Groarke EM, Lotter J, Shalhoub R, Gutierrez-Rodrigues F, Rios O, et al. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood. 2022;139(1):34–43. https://doi.org/10.1182/blood.2021012130.CrossRefPubMedPubMedCentral

33.

Peffault-de-Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386(1):11–23. https://doi.org/10.1056/NEJMoa2109965.CrossRefPubMed

34.

Scheinberg P. A new standard immunosuppression regimen in severe aplastic anemia. N Engl J Med. 2022;386(1):89–90. https://doi.org/10.1056/NEJMe2118143.CrossRefPubMed

35.

Marsh JC. Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia. Semin Hematol. 2000;37(1):81–90.CrossRefPubMed

36.

Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685–97. https://doi.org/10.1016/j.stem.2007.10.020.CrossRefPubMed

37.

Ballmaier M, Germeshausen M, Krukemeier S, Welte K. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci. 2003;996:17–25.ADSCrossRefPubMed

38.

Feng X, Scheinberg P, Wu CO, Samsel L, Nunez O, Prince C, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica. 2011;96(4):602–6. https://doi.org/10.3324/haematol.2010.030536.CrossRefPubMed

39.

Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica. 2009;94(3):310–2. https://doi.org/10.3324/haematol.2008.002329.CrossRefPubMedPubMedCentral

40.

Huang AT, Mold NG, Zhang SF. Antithymocyte globulin stimulates human hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987;84(16):5942–6.ADSCrossRefPubMedPubMedCentral

41.

Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Blood Adv. 2018;2(21):3054–62. https://doi.org/10.1182/bloodadvances.2018020248.CrossRefPubMedPubMedCentral

42.

Alvarado LJ, Andreoni A, Huntsman HD, Cheng H, Knutson JR, Larochelle A. Heterodimerization of TPO and IFNγ impairs human hematopoietic stem/progenitor cell signaling and survival in chronic inflammation. Blood. 2017;130(Suppl 1):4.

43.

Goronkova O, Novichkova G, Salimova T, Kalinina I, Baidildina D, Petrova U, et al. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. Blood Adv. 2023;7(6):953–62. https://doi.org/10.1182/bloodadvances.2021006716.CrossRefPubMed

44.

Groarke EM, Patel BA, Gutierrez-Rodrigues F, Rios O, Lotter J, Baldoni D, et al. Eltrombopag added to immunosuppression for children with treatment-naive severe aplastic anaemia. Br J Haematol. 2021;192(3):605–14. https://doi.org/10.1111/bjh.17232.CrossRefPubMedPubMedCentral

45.

Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr. 2008;153(6):814–9. https://doi.org/10.1016/j.jpeds.2008.06.004.CrossRefPubMedPubMedCentral

46.

Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–56. https://doi.org/10.1056/NEJMra1413485.CrossRefPubMedPubMedCentral

47.

Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1):35–47. https://doi.org/10.1056/NEJMoa1414799.CrossRefPubMedPubMedCentral

48.

Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018;124(21):4192–201. https://doi.org/10.1002/cncr.31658.CrossRefPubMed

Title: Progress in medical therapy in aplastic anemia: why it took so long?
Author: Phillip Scheinberg
Publication date: 26-02-2024
Publisher: Springer Nature Singapore
Keywords: Aplastic Anemia
Anemia
Published in: International Journal of Hematology / Issue 3/2024
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-024-03713-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

Differences between Japanese new criteria and pregnancy-specific modified ISTH DIC scores for obstetrical DIC diagnosis

Allogeneic bone marrow transplantation for aplastic anemia

Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors

Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia

Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib

HLA-haploidentical T-cell receptor αβT/B-cell-depleted stem cell transplantation for Fanconi anemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer